Literature DB >> 26334709

Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation.

Daisuke Izumi1, Masatoshi Miyahara2, Naoki Fujimoto3, Shusuke Fukuoka2, Masataka Sakai2, Kaoru Dohi4, Masaaki Ito4.   

Abstract

Our objective was to clarify whether thrombogenic problems with stent struts are resolved at 3 months after 2nd-generation drug-eluting stent implantation. Twenty-one patients with stable angina pectoris having 28 (22 zotarolimus-eluting, 6 everolimus-eluting) stents with optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) were evaluated. Stent strut coverage and malapposition were evaluated by OCT immediately after PCI and at 3-month follow-up. Acute strut malapposition was observed in 26 out of 28 analyzed stents (92.9 %). At 3-month follow-up, 7 (26.9 %) of those 26 stents with strut malapposition were completely resolved, and the mean percentages of uncovered struts and malapposed struts were 8.3 and 2.0 % when analyzed by each individual stent. When analyzing a total of 30,060 struts, 807 struts (2.7 %) demonstrated acute strut malapposition. Among these, 219 struts (27.1 %) demonstrated persistent strut malapposition. On the basis of receiver-operating characteristic curve analysis, a strut-to-vessel (S-V) distance ≤160 µm on post-stenting OCT images was the corresponding cutoff point for resolved malapposed struts (sensitivity 78.1 %, specificity 62.8 %, area under the curve 0.758). The S-V distance of persistent malapposed struts on post-stenting OCT images was longer than that of resolved malapposed struts (235 ± 112 vs. 176 ± 93 µm, p < 0.01). At 3 months after PCI, the prevalence rates of uncovered and malapposed struts were relatively low in 2nd-generation drug-eluting stent. Our results suggest that OCT-guide PCI with an S-V distance ≤160 µm may be recommended especially in patients with planed short-term DAPT.

Entities:  

Keywords:  Drug-eluting stents; Optical coherence tomography; Strut malapposition

Mesh:

Substances:

Year:  2015        PMID: 26334709     DOI: 10.1007/s00380-015-0737-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  28 in total

1.  Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound.

Authors:  Ik-Kyung Jang; Brett E Bouma; Dong-Heon Kang; Seung-Jung Park; Seong-Wook Park; Ki-Bae Seung; Kyu-Bo Choi; Milen Shishkov; Kelly Schlendorf; Eugene Pomerantsev; Stuart L Houser; H Thomas Aretz; Guillermo J Tearney
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

2.  Comparison of contrast media and low-molecular-weight dextran for frequency-domain optical coherence tomography.

Authors:  Yuichi Ozaki; Hironori Kitabata; Hiroto Tsujioka; Seiki Hosokawa; Manabu Kashiwagi; Kohei Ishibashi; Kenichi Komukai; Takashi Tanimoto; Yasushi Ino; Shigeho Takarada; Takashi Kubo; Keizo Kimura; Atsushi Tanaka; Kumiko Hirata; Masato Mizukoshi; Toshio Imanishi; Takashi Akasaka
Journal:  Circ J       Date:  2012-02-03       Impact factor: 2.993

3.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Authors:  Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272

4.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Authors:  Byeong-Keuk Kim; Myeong-Ki Hong; Dong-Ho Shin; Chung-Mo Nam; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Tae-Soo Kang; Byoung-Eun Park; Woong-Chol Kang; Seung-Hwan Lee; Jung-Han Yoon; Bum-Kee Hong; Hyuck-Moon Kwon; Yangsoo Jang
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

5.  Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation.

Authors:  Hoyoun Won; Dong-Ho Shin; Byeong-Keuk Kim; Gary S Mintz; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Int J Cardiovasc Imaging       Date:  2013-04-25       Impact factor: 2.357

6.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.

Authors:  Eric L Eisenstein; Kevin J Anstrom; David F Kong; Linda K Shaw; Robert H Tuttle; Daniel B Mark; Judith M Kramer; Robert A Harrington; David B Matchar; David E Kandzari; Eric D Peterson; Kevin A Schulman; Robert M Califf
Journal:  JAMA       Date:  2006-12-05       Impact factor: 56.272

7.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

8.  Incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation.

Authors:  Eui Im; Byeong-Keuk Kim; Young-Guk Ko; Dong-Ho Shin; Jung-Sun Kim; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Circ Cardiovasc Interv       Date:  2014-01-14       Impact factor: 6.546

Review 9.  Stent thrombosis with drug-eluting stents: is the paradigm shifting?

Authors:  Tullio Palmerini; Giuseppe Biondi-Zoccai; Diego Della Riva; Andrea Mariani; Philippe Genereux; Angelo Branzi; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-09-11       Impact factor: 24.094

10.  Fusion of 3D QCA and IVUS/OCT.

Authors:  Shengxian Tu; Niels R Holm; Gerhard Koning; Zheng Huang; Johan H C Reiber
Journal:  Int J Cardiovasc Imaging       Date:  2011-01-25       Impact factor: 2.357

View more
  4 in total

1.  Cut-off value of mal-apposition volume and depth for resolution at early phase of acute incomplete stent apposition after CoCr-EES implantation.

Authors:  Yohei Uchimura; Tomonori Itoh; Hideto Oda; Yuya Taguchi; Wataru Sasaki; Kyosuke Kaneko; Tsubasa Sakamoto; Iwao Goto; Masafumi Sakuma; Masaru Ishida; Tatsuo Kikuchi; Daisuke Terashita; Hiromasa Otake; Yoshihiro Morino; Toshiro Shinke
Journal:  Int J Cardiovasc Imaging       Date:  2019-06-29       Impact factor: 2.357

2.  New scoring model (DARSYM score) to predict post-discharge bleeding after successful second-generation drug-eluting stent implantation.

Authors:  Yohsuke Honda; Masahiro Yamawaki; Keisuke Hirano; Motoharu Araki; Norihiro Kobayashi; Yasunari Sakamoto; Shinsuke Mori; Masakazu Tsutumi; Takuro Takama; Takahiro Tokuda; Kenji Makino; Shigemitsu Shirai; Yoshiaki Ito
Journal:  Heart Vessels       Date:  2017-05-30       Impact factor: 2.037

3.  Randomised trial of the comparison of drug-eluting stents in patients with diabetes: OCT DES trial.

Authors:  Stephen Hamshere; Alex Byrne; Tawfiq Choudhury; Sean M Gallagher; Krishnaraj S Rathod; Julia Lungley; Charles J Knight; Akhil Kapur; Daniel A Jones; Anthony Mathur
Journal:  Open Heart       Date:  2018-04-05

4.  Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study.

Authors:  Tomasz Roleder; Elvin Kedhi; Balazs Berta; Pawel Gasior; Wojciech Wanha; Magda Roleder; Joanna Fluder; Grzegorz Smolka; Andrzej Ochala; Wojciech Wojakowski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-06-26       Impact factor: 1.426

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.